Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.

Date publication

septembre 2018

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CORNILLET-LEFEBVRE Pascale , Pr FORNECKER Luc-Matthieu , Dr OJEDA-URIBE Mario

Tous les auteurs :
Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, Guièze R, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard M, Jourdan E, Vey N, Zerazhi H, Hishri Y, Mineur A, Asselineau J, Delepine R, Cahn JY, Ifrah N, Récher C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30260758

Résumé

Acute myeloid leukemia (AML) in elderly patients has a poor prognosis. In an attempt to improve outcome for these patients, the prospective open-label phase III LAM-SA 2007 (Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old) trial randomly assigned patients to a standard induction regimen with lomustine added or to a consolidation regimen with cytarabine and idarubicin.

Référence

J. Clin. Oncol.. 2018 Sep 27;:JCO2018787366